Date: Sunday, November 8, 2015
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Despite their profound inhibitory effects on inflammation and bone destruction, it remains unclear whether biological therapies can improve the long-term prognosis of patients with rheumatoid arthritis (RA). Enhanced risk of atherosclerotic cardiovascular (CV) disease is a key feature of RA. Oxidative stress is closely associated with the process of atherosclerosis. In the present study we have investigated the correlation between efficacy of 52-week treatment with tocilizumab (TCZ) and levels of oxidative stress markers in patients with RA.
Methods: Patients treated with TCZ were prospectively studied with informed consent. Efficacy of TCZ and levels of 8-OHdG and 8-iso-PGF2a in urine were evaluated by enzyme immunoassay and enzyme-linked immunosorbent assay, respectively, at baseline and 52 weeks.
Results: Thirty out of 82 patients with RA (mean age 61.0 years old; mean disease duration 7.5 years; concomitant MTX 60%) were studied at the 52-week analysis. The rate of DAS28 (ESR) and CDAI remission at 52 weeks was 76.7% and 33.3%, respectively. In all patients levels of 8-OHdG in urine were decreased (at baseline, 12.5 ng/mg Cr; at 6 months, 9.5 ng/mg Cr), while levels of 8-iso-PGF2a in urine were not altered (at baseline, 355.4 pg/mg Cr; at 6 months, 387.4 pg/mg Cr). Intriguingly, however, levels of 8-OHdG and 8-iso-PGF2a were both decreased in a subgroup of patients with RA who took concomitant MTX, at an early stage of disease, or achieved CDAI remission.
Conclusion: Efficacy of 52-week treatment with TCZ correlated with reduced levels of oxidative stress markers in RA patients. This trend was noted in a subpopulation of patients with RA who took concomitant MTX, at an early stage of disease, or achieved CDAI remission. Together, these findings suggest that treatment with TCZ improves the long-term prognosis of patients with RA by lowering the risk of CV events.
To cite this abstract in AMA style:Niiro H, Tsukamoto H, Arinobu Y, Akahoshi M, Mitoma H, Oryoji K, Inoue Y, Sawabe T, Nagano S, Nishizaka H, Yoshizawa S, Tada Y, Yoshizawa S, Otsuka T, Ueda A, Nakashima H, Horiuchi T, Akashi K. Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/correlation-between-efficacy-of-tocilizumab-and-levels-of-oxidative-stress-markers-in-patients-with-rheumatoid-arthritis-the-52-week-analysis/. Accessed January 21, 2022.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-between-efficacy-of-tocilizumab-and-levels-of-oxidative-stress-markers-in-patients-with-rheumatoid-arthritis-the-52-week-analysis/